CY1124349T1 - Νεα αλατα και φαρμακευτικες συνθεσεις αυτων για την αντιμετωπιση φλεγμονωδων διαταραχων - Google Patents
Νεα αλατα και φαρμακευτικες συνθεσεις αυτων για την αντιμετωπιση φλεγμονωδων διαταραχωνInfo
- Publication number
- CY1124349T1 CY1124349T1 CY20211100080T CY211100080T CY1124349T1 CY 1124349 T1 CY1124349 T1 CY 1124349T1 CY 20211100080 T CY20211100080 T CY 20211100080T CY 211100080 T CY211100080 T CY 211100080T CY 1124349 T1 CY1124349 T1 CY 1124349T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- pharmaceutical compositions
- diseases
- inflammatory disorders
- new salts
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010058314 Dysplasia Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/04—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks
- H04L63/0428—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks wherein the data content is protected, e.g. by encrypting or encapsulating the payload
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/06—Network architectures or network communication protocols for network security for supporting key management in a packet data network
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/08—Network architectures or network communication protocols for network security for authentication of entities
- H04L63/0861—Network architectures or network communication protocols for network security for authentication of entities using biometrical features, e.g. fingerprint, retina-scan
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/20—Network architectures or network communication protocols for network security for managing network security; network security policies in general
- H04L63/205—Network architectures or network communication protocols for network security for managing network security; network security policies in general involving negotiation or determination of the one or more network security mechanisms to be used, e.g. by negotiation between the client and the server or between peers or by selection according to the capabilities of the entities involved
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/01—Protocols
- H04L67/10—Protocols in which an application is distributed across nodes in the network
- H04L67/104—Peer-to-peer [P2P] networks
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/50—Network services
- H04L67/51—Discovery or management thereof, e.g. service location protocol [SLP] or web services
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/80—Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W8/00—Network data management
- H04W8/22—Processing or transfer of terminal data, e.g. status or physical capabilities
- H04W8/24—Transfer of terminal data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W92/00—Interfaces specially adapted for wireless communication networks
- H04W92/16—Interfaces between hierarchically similar devices
- H04W92/18—Interfaces between hierarchically similar devices between terminal devices
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Computer Security & Cryptography (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Computing Systems (AREA)
- Computer Hardware Design (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Databases & Information Systems (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1402071.3A GB201402071D0 (en) | 2014-02-07 | 2014-02-07 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2015/052242 WO2015117981A1 (en) | 2014-02-07 | 2015-02-04 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124349T1 true CY1124349T1 (el) | 2022-07-22 |
Family
ID=50390572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100080T CY1124349T1 (el) | 2014-02-07 | 2021-02-01 | Νεα αλατα και φαρμακευτικες συνθεσεις αυτων για την αντιμετωπιση φλεγμονωδων διαταραχων |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US9382247B2 (enExample) |
| EP (2) | EP3102575B1 (enExample) |
| JP (2) | JP2017505329A (enExample) |
| KR (1) | KR102478614B1 (enExample) |
| CN (2) | CN111499630A (enExample) |
| AR (1) | AR099307A1 (enExample) |
| AU (4) | AU2015215045B2 (enExample) |
| CA (1) | CA2938219C (enExample) |
| CY (1) | CY1124349T1 (enExample) |
| DK (1) | DK3102575T3 (enExample) |
| EA (2) | EA201990330A1 (enExample) |
| ES (1) | ES2853375T3 (enExample) |
| GB (1) | GB201402071D0 (enExample) |
| HR (1) | HRP20210194T1 (enExample) |
| HU (1) | HUE053309T2 (enExample) |
| IL (1) | IL246833B (enExample) |
| LT (1) | LT3102575T (enExample) |
| MX (2) | MX395415B (enExample) |
| NZ (1) | NZ722603A (enExample) |
| PL (1) | PL3102575T3 (enExample) |
| PT (1) | PT3102575T (enExample) |
| RS (1) | RS61450B1 (enExample) |
| SG (2) | SG11201606433PA (enExample) |
| SI (1) | SI3102575T1 (enExample) |
| SM (1) | SMT202100060T1 (enExample) |
| TW (2) | TWI767878B (enExample) |
| UY (1) | UY35984A (enExample) |
| WO (1) | WO2015117981A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| KR20170134750A (ko) * | 2015-04-13 | 2017-12-06 | 갈라파고스 엔.브이. | 염증 질환의 치료 방법 |
| SMT202300328T1 (it) * | 2015-04-13 | 2023-11-13 | Galapagos Nv | Metodi per il trattamento di disturbi cardiovascolari |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
| CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
| CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
| CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
| CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
| CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
| CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
| CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| WO2017106566A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| CN105669669A (zh) * | 2016-03-04 | 2016-06-15 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法 |
| KR20180120273A (ko) * | 2016-03-21 | 2018-11-05 | 크리스탈 파마테크 씨오., 엘티디. | Jak 관련 질병 예방 또는 치료용 약물의 염산 결정성 형태 및 이의 제조 방법 |
| WO2018024236A1 (zh) * | 2016-08-03 | 2018-02-08 | 苏州科睿思制药有限公司 | 一种jak1选择性抑制剂的新晶型及其制备方法和用途 |
| JP2019534304A (ja) | 2016-11-10 | 2019-11-28 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 炎症性疾患の治療のための化合物及びその医薬組成物 |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| FI3595667T3 (fi) * | 2017-03-14 | 2024-01-12 | Galapagos Nv | Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| US10815227B2 (en) | 2018-08-27 | 2020-10-27 | Cadila Healthcare Limited | Processes for the preparation of filgotinib |
| WO2020092245A1 (en) * | 2018-10-29 | 2020-05-07 | Zorday IP, LLC | Network-enabled electronic cigarette |
| WO2020177705A1 (zh) * | 2019-03-05 | 2020-09-10 | 苏州科睿思制药有限公司 | Filgotinib的马来酸盐晶型CSI及其制备方法和用途 |
| WO2020201975A2 (en) * | 2019-03-30 | 2020-10-08 | Unichem Laboratories Limited | Novel process for the preparation of filgotinib and intermediates thereof |
| WO2021044327A1 (en) * | 2019-09-03 | 2021-03-11 | Dr. Reddy's Laboratories Limited | Solid forms of filgotinib maleate and processes thereof |
| CN114075188A (zh) * | 2020-08-11 | 2022-02-22 | 南京柯菲平盛辉制药有限公司 | 芳香杂环酰胺类化合物及其制备方法和医药用途 |
| AU2021397808A1 (en) * | 2020-12-09 | 2023-07-06 | Servatus Ltd | Combination therapy for inflammatory disorders of the joints |
| CN113773322B (zh) * | 2021-11-10 | 2022-02-11 | 奥锐特药业(天津)有限公司 | 一种Filgotinib的制备方法 |
| WO2026027669A1 (en) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarkers for determining treatment of ulcerative colitis with filgotinib |
| WO2026027676A1 (en) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarkers for determining treatment of ulcerative colitis with filgotinib |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2549632B2 (ja) * | 1986-08-20 | 1996-10-30 | 三井石油化学工業株式会社 | オレフインの重合方法 |
| EP1156037B1 (en) | 1999-01-29 | 2004-12-01 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| WO2004039816A1 (ja) * | 2002-10-29 | 2004-05-13 | Shionogi & Co., Ltd. | セフェム化合物の無機酸塩の結晶 |
| EP1601672B1 (en) | 2003-02-14 | 2006-07-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| MX2007002050A (es) | 2004-08-18 | 2007-03-29 | Pharmacia & Upjohn Co Llc | Compuestos de triazolopiridina. |
| EP1799680A2 (en) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| JP5352476B2 (ja) | 2007-06-05 | 2013-11-27 | 武田薬品工業株式会社 | キナーゼ阻害剤としての二環式複素環化合物 |
| CN101801966A (zh) | 2007-07-18 | 2010-08-11 | 诺瓦提斯公司 | 双环杂芳基化合物和它们作为激酶抑制剂的用途 |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| US20110124692A1 (en) * | 2008-07-31 | 2011-05-26 | Daiichi Sankyo Company, Limited | Crystalline forms of thiazolidinedione compound and its manufacturing method |
| WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| US20120245346A1 (en) * | 2009-09-25 | 2012-09-27 | Kyorin Pharmaceutical Co., Ltd. | Maleic acid salt and crystal thereof |
| CN102146082A (zh) * | 2010-02-04 | 2011-08-10 | 江苏恒瑞医药股份有限公司 | 吡咯并n杂环类衍生物的可药用的盐、其制备方法及其在医药上的应用 |
| JP2013049632A (ja) * | 2011-08-30 | 2013-03-14 | Kowa Co | ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤 |
| SA112330992B1 (ar) | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| MX368511B (es) | 2012-06-22 | 2019-10-07 | Galapagos Nv | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma. |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| KR20170134750A (ko) | 2015-04-13 | 2017-12-06 | 갈라파고스 엔.브이. | 염증 질환의 치료 방법 |
| SMT202300328T1 (it) | 2015-04-13 | 2023-11-13 | Galapagos Nv | Metodi per il trattamento di disturbi cardiovascolari |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| FI3595667T3 (fi) | 2017-03-14 | 2024-01-12 | Galapagos Nv | Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
-
2014
- 2014-02-07 GB GBGB1402071.3A patent/GB201402071D0/en not_active Ceased
-
2015
- 2015-02-04 SM SM20210060T patent/SMT202100060T1/it unknown
- 2015-02-04 MX MX2020003368A patent/MX395415B/es unknown
- 2015-02-04 CA CA2938219A patent/CA2938219C/en active Active
- 2015-02-04 KR KR1020167023807A patent/KR102478614B1/ko active Active
- 2015-02-04 AU AU2015215045A patent/AU2015215045B2/en active Active
- 2015-02-04 MX MX2016010068A patent/MX376000B/es active IP Right Grant
- 2015-02-04 JP JP2016550633A patent/JP2017505329A/ja active Pending
- 2015-02-04 HR HRP20210194TT patent/HRP20210194T1/hr unknown
- 2015-02-04 ES ES15704974T patent/ES2853375T3/es active Active
- 2015-02-04 EP EP15704974.3A patent/EP3102575B1/en active Active
- 2015-02-04 CN CN202010324636.7A patent/CN111499630A/zh active Pending
- 2015-02-04 DK DK15704974.3T patent/DK3102575T3/da active
- 2015-02-04 PT PT157049743T patent/PT3102575T/pt unknown
- 2015-02-04 RS RS20210134A patent/RS61450B1/sr unknown
- 2015-02-04 CN CN201580006893.3A patent/CN105960407A/zh active Pending
- 2015-02-04 NZ NZ722603A patent/NZ722603A/en unknown
- 2015-02-04 EP EP20211405.4A patent/EP3842432A1/en not_active Withdrawn
- 2015-02-04 EA EA201990330A patent/EA201990330A1/ru unknown
- 2015-02-04 SG SG11201606433PA patent/SG11201606433PA/en unknown
- 2015-02-04 WO PCT/EP2015/052242 patent/WO2015117981A1/en not_active Ceased
- 2015-02-04 LT LTEP15704974.3T patent/LT3102575T/lt unknown
- 2015-02-04 HU HUE15704974A patent/HUE053309T2/hu unknown
- 2015-02-04 IL IL246833A patent/IL246833B/en unknown
- 2015-02-04 SI SI201531491T patent/SI3102575T1/sl unknown
- 2015-02-04 EA EA201691584A patent/EA032596B1/ru unknown
- 2015-02-04 US US14/614,396 patent/US9382247B2/en active Active
- 2015-02-04 PL PL15704974T patent/PL3102575T3/pl unknown
- 2015-02-04 SG SG10202013187PA patent/SG10202013187PA/en unknown
- 2015-02-06 AR ARP150100351A patent/AR099307A1/es unknown
- 2015-02-06 UY UY0001035984A patent/UY35984A/es not_active Application Discontinuation
- 2015-02-06 TW TW104104160A patent/TWI767878B/zh active
- 2015-02-06 TW TW110136599A patent/TWI792593B/zh active
-
2016
- 2016-07-01 US US15/200,228 patent/US20160376269A1/en not_active Abandoned
-
2017
- 2017-07-10 US US15/645,308 patent/US10708263B2/en active Active
-
2019
- 2019-04-08 AU AU2019202441A patent/AU2019202441B2/en active Active
- 2019-09-30 US US16/588,207 patent/US10919890B2/en active Active
-
2020
- 2020-01-28 JP JP2020011555A patent/JP2020097595A/ja active Pending
- 2020-10-26 AU AU2020260391A patent/AU2020260391B2/en active Active
-
2021
- 2021-01-08 US US17/144,788 patent/US11667633B2/en active Active
- 2021-02-01 CY CY20211100080T patent/CY1124349T1/el unknown
-
2022
- 2022-09-23 AU AU2022235624A patent/AU2022235624B2/en active Active
-
2023
- 2023-04-25 US US18/306,867 patent/US12234235B2/en active Active
-
2025
- 2025-01-22 US US19/033,986 patent/US20250289816A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010068A (es) | Sales novedosas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| CL2021001078A1 (es) | 2-amino-n-heteroarilo-nicotinamidas como inhibidores de nav1.8. | |
| CY1122631T1 (el) | Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων | |
| IL284577A (en) | Gene therapy | |
| TW201613601A (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| IL282386A (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors | |
| BR112018009706A8 (pt) | composições compreendendo cepas bacterianas | |
| BR112018009213A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112018009184A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112017025005A2 (pt) | composições compreendendo cepas baterianas | |
| IL251708A0 (en) | Social scores for network elements | |
| BR112017025003A2 (pt) | composições compreendendo cepas bacterianas | |
| GEAP201914307A (en) | 4'-substituted nucleosidederivatives as hiv reverse transcriptase inhibitors | |
| DK3328414T3 (da) | Sammensætning til anvendelse i fremme af sårheling | |
| BR112017023110A2 (pt) | composição de curativo de ferida, método de fabricação da mesma, e, uso de uma composição de curativo de ferida | |
| FR3040468B1 (fr) | Lampe | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| CY1123465T1 (el) | Αντιβακτηριακες ενωσεις ευρεως φασματος | |
| EP3778967A4 (en) | Railroad axle | |
| EA202191471A1 (ru) | Противовоспалительные полипептиды | |
| EP3392552A4 (en) | LAMP | |
| EP3572713A4 (en) | LAMP | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы |